Roberta Sanfilippo; Nadia Hindi; Josefina Cruz Jurado; Jean-Yves Blay; Antonio Lopez-Pousa; Antoine Italiano; Rosa Alvarez; Antonio Gutierrez; Inmaculada Rincón-Perez; Claudia Sangalli; Jose Luis Pérez Aguiar; Jesús Romero; Carlo Morosi; Marie-Pierre Sunyach; Chiara Fabbroni; Cleofe Romagosa; Dominique Ranchere-Vince; Angelo P. Dei Tos; Paolo G. Casali; Javier Martin-Broto; Alessandro Gronchi. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients with Myxoid Liposarcoma. A Non-randomized Clinical Trial.
JAMA Oncol. Published online March 30, 2023. doi:10.1001/jamaoncol.2023.0056. (GEIS-37)
Jose Alejandro Pérez-Fidalgo, Eugenia Ortega, Jordi Ponce, Andres Redondo, Isabel Sevilla, Claudia Valverde, Josep Isern Verdum, Enrique de Alava, Mar Galera López, Gloria Marquina, Ana Sebio. Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS).
Ther Adv Med Oncol. 2023 Mar 28. PMID: 37007636 PMCID: PMC10052607 DOI: 10.1177/17588359231157645.
César Serrano, Rosa Álvarez, Juan Antonio Carrasco, Gloria Marquina, Jerónimo Martínez‑García, Virginia Martínez‑Marín, María Ángeles Sala, Ana Sebio, Isabel Sevilla, Javier Martín‑Broto. SEOM‑GEIS clinical guideline for gastrointestinal stromal tumors (2022).
Clinical and Translational Oncology. https://doi.org/10.1007/s12094-023-03177-7.
Emanuela Palmerini, Marco Gambarotti, Antoine Italiano, Michael J. Nathenson, Ravin Ratan, Palma Dileo, Salvatore Provenzano, Robin L. Jones, Steven G. DuBois, Javier Martin-Broto, Enrique de Alava, Giacomo G. Baldi, Giovanni Grignani, Virginia Ferraresi, Antonella Brunello, Luca Paoluzzi, Rossella Bertulli, Nadia Hindi, Michael Montemurro, Christian Rothermundt, Stefania Cocchi, Carmen Salguero-Aranda, Davide Donati, Juan D. Martin, Amr H. Abdelhamid Ahmed, Alessandro Mazzocca, Elisa Carretta, Marilena Cesari, Michela Pierini, Alberto Righi, Marta Sbaraglia, Maria A. Laginestra, Katia Scotlandi, Angelo P. Dei Tos, Toni Ibrahim, Silvia Stacchiotti, Bruno Vincenzi. A global collaboRAtive study of CIC-rearranged, BCOR: CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl). (GEIS-72).
European Journal of Cancer. 2023 Jan 18;183:11-23. doi: 10.1016/j.ejca.2023.01.003. Online ahead of print.
Bernadette Brennan, Laura Kirton, Perrine Marec-Bérard, Nathalie Gaspar, Valerie Laurence, Javier Martín-Broto, Ana Sastre, Hans Gelderblom, Cormac Owens, Nicola Fenwick, Sandra Strauss, Veronica Moroz, Jeremy Whelan, Keith Wheatley. Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
The Lancet, Volume 400, Issue 10362, 29 October–4 November 2022, Pages 1513-1521. (GEIS-34)
Samuel Hidalgo-Ríos, Jaime Carrillo-García, David S Moura, Silvia Stacchiotti, Antonio López-Pousa, Andrés Redondo, Antoine Italiano, Antonio Gutiérrez, Giovanni Grignani, Nadia Hindi, José-Antonio López-Guerrero, Xavier García Del Muro, Javier Martínez Trufero, Emanuela Palmerini, Ana Sebio García, Daniel Bernabeu, Axel Le Cesne, Paolo Giovanni Casali, Jean-Yves Blay, Josefina Cruz Jurado 18, Javier Martin-Broto. Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib.
Cancers (Basel). 2022 Aug 29;14(17):4186. doi: 10.3390/cancers14174186.(GEIS-32)
Andrea Napolitano, David S Moura, Nadia Hindi, José L Mondaza-Hernandez, José A Merino-Garcia, Rafael Ramos, Gian Paolo Dagrada, Silvia Stacchiotti, Francesco Graziano, Bruno Vincenzi, Javier Martin-Broto. Expression of p53 as a biomarker of pazopanib efficacy in solitary fibrous tumours: translational analysis of a phase II trial.
Ther Adv Med Oncol. 2022 Aug 6;14:17588359221116155. doi: 10.1177/17588359221116155. eCollection 2022. (GEIS-32)
Javier Martin-Broto, Andres Redondo, David S. Moura, Claudia Valverde, Jose Manuel Morales, Antonio Lopez-Pousa, Javier Martinez-Trufero, Antonio Gutierrez, Roberto Díaz-Beveridge, Pablo Luna, Virginia Martinez-Marin, David Marcilla, Ivan Arribas, Patricio Ledesma, Jose Antonio Lopez-Martin, Davide Di Lernia, Jorge Zamora & Nadia Hindi. A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors.
Nature Communications volume 13, Article number: 6278 (2022). (GEIS-39)
Jose L. Mondaza‑Hernandez, David S. Moura, María Lopez‑Alvarez, Paloma Sanchez‑Bustos, Elena Blanco‑Alcaina, Carolina Castilla‑Ramirez, Paola Collini, Jose Merino‑Garcia, Jorge Zamora, Jaime Carrillo‑Garcia, Roberta Maestro, Nadia Hindi,Jesus Garcia‑Foncillas, Javier Martin‑Broto. ISG15 as a prognostic biomarker in solitary fibrous tumour.
Cellular and Molecular Life Sciences (2022) 79:434. https://doi.org/10.1007/s00018-022-04454-4. (GEIS-32)
Martin McCabe, Laura Kirton, Maria Khan, Nicola Fenwick, Sandra J. Strauss, Claudia Valverde, Cristina Mata, Nathalie Gaspar, Roberto Luksch, Alessandra Longhi, Uta Dirksen, Marianne Phillips, Akmal Safwat, Hans Gelderblom, Thomas Kuehne, Jukka Kanerva, Andrew J. Westwood, Stefano Ferrari, Jeremy Whelan, Keith Wheatley. Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).
LBA2 Journal of Clinical Oncology 40, no. 17_suppl (June 10, 2022) LBA2-LBA2. Published online June 08, 2022. (GEIS-35) DOI: 10.1200/JCO.2022.40.17_suppl.
Javier Martínez-Trufero, Luis Miguel De Sande-González, Pablo Luna, Javier Martin-Broto, Rosa Alvarez, Gloria Marquina, Roberto Diaz-Beveridge, Andrés Poveda, Juana María Cano, Josefina Cruz-Jurado, Antonio López Pousa, María Angeles Vaz Salgado, Claudia M Valverde-Morales, Isabel Sevilla, Jerónimo Martínez-García, Jordi Rubio-Casadevall, Ana De Juan, Juan Antonio Carrasco, David S Moura, Ibon Gurruchaga-Sotes, Antonio Gutiérrez. Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study.
Cancers (Basel). 2021 Feb 14;13(4):792. doi: 10.3390/cancers13040792. (GEIS-38)
G Casali, A Le Cesne, A P Velasco, D Kotasek, P Rutkowski, P Hohenberger, E Fumagalli, I R Judson, A Italiano, H Gelderblom, N Penel, J T Hartmann, F Duffaud, D Goldstein, J Martin-Broto, A Gronchi, E Wardelmann, S Marréaud, J R Zalcberg, S Litière, J-Y Blay. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS).
Ann Oncol. 2021 Apr; 32(4):533-541. doi: 10.1016/j.annonc.2021.01.004. Epub 2021 Jan 19.
Martin-Broto J, Hindi N, Grignani G, Martinez-Trufero J, Redondo A, Valverde C, Stacchiotti S, Lopez-Pousa A, D'Ambrosio L, Gutierrez A, Perez-Vega H, Encinas-Tobajas V, De Alava E, Collini P, Peña-Chilet M, Dopazo J, Carrasco-Garcia I, Lopez-Alvarez M, Moura D S, Lopez-Martin JA. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial.
J Immunother Cancer: first published as 10.1136/jitc-2020-001561 on 17 November 2020.(GEIS-52)
Antonio Fernandez-Serra, David S. Moura, María Dolores Sanchez-Izquierdo, Silvia Calabuig-Fariñas, Maria Lopez-Alvarez, Andrea Martínez-Martínez, Irene Carrasco-Garcia, Marta Ramírez-Calvo, Elena Blanco-Alcaina, Raquel López-Reig, Antonia Obrador-Hevia, Regina Alemany, Antonio Gutierrez, Nadia Hindi, Andres Poveda, Jose A. Lopez-Guerrero, and Javier Martin-Broto. Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study.
Cancers 2020, 12, 2979; doi:10.3390/cancers12102979.(GEIS-31)
Javier Martín Broto, Nadia Hindi, Samuel Aguiar Jr, Ronal Badilla-González, Víctor Castro-Oliden, Matías Chacón, Raquel Correa-Generoso, Enrique De Alava, Davide María Donati, Mikael Eriksson, Martín Falla-Jiménez, Gisela Germán, María Leticia Gobo Silva, Francois Gouin, Alessandro Gronchi, Juan Carlos Haro-Varas, Natalia Jiménez-Brenes, Bernd Kasper, Celso Abdon Lopes de Mello, Robert Maki, Paula Martínez-Delgado, Héctor Martínez-Said, Jorge Luis Martínez-Tlahuel, José Manuel Morales-Pérez, Francisco Cristóbal Muñoz-Casares, Suely A. Nakagawa, Eduardo José Ortiz-Cruz, Emanuela Palmerini, Shresyaskumar Patel, David S. Moura, Silvia Stacchiotti, Marie Pierre Sunyach, Claudia M. Valverde, Federico Weisberg, Jean-Yves Blay. Sarcoma European & Latin American Network (SELNET) recommendations on prioritization in sarcoma care during COVID-19 pandemic.
The Oncologist 2020;25:e1562–e1573. (SELNET)
Martin-Broto, J; Hindi, N; Lopez-Pousa, A; Peinado-Serrano, J; Alvarez, R; Alvarez-Gonzalez, A; Italiano, A; Sargos, P; Cruz-Jurado, J; Isern-Verdum, J; Dolado, MC; Rincon-Pérez, I; Sanchez-Bustos, P; Gutierrez, A; Romagosa, C; Morosi, C; Grignani, G; Marco Gatti, MD17; Luna, P; Alastuey, I; Redondo, A; Belinchon, B; Martinez-Serra, J; Sunyach, M-P; Coindre, J-M; Dei Tos, A; Romero, J; Gronchi, A; Blay, J-Y; Moura, D. Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients with Metastatic Soft-Tissue Sarcomas. A non-randomized Phase 1/2 Clinical Trial.
JAMA Oncol. 2020;6(4):535-541. doi:10.1001/jamaoncol.2019.6584. (GEIS 37.)
Javier Martin-Broto, Silvia Stacchiotti, Antonio Lopez-Pousa, Andres Redondo, Daniel Bernabeu, Enrique de Alava, Paolo G Casali, Antoine Italiano, Antonio Gutierrez, David S Moura, Maria Peña-Chilet, Juan Diaz-Martin, Michele Biscuola, Miguel Taron, Paola Collini, Dominique Ranchere-Vince, Xavier Garcia del Muro, Giovanni Grignani, Sarah Dumont, Javier Martinez-Trufero, Emanuela Palmerini, Nadia Hindi, Ana Sebio, Joaquin Dopazo, Angelo Paolo Dei Tos, Axel LeCesne, Prof Jean-Yves Blay, Josefina Cruz. Pazopanib for treatment of typical solitary fibrous tumour: a multicentre single-arm, phase II trial.
The Lancet Oncology. vol. 21, issue 3, p456-466. March 01, 2020. (GEIS 32.)
Jennifer Anderton, Veronica Moroz, Perrine Marec-Bérard, Nathalie Gaspar, Valerie Laurence, Javier Martín-Broto, Ana Sastre, Hans Gelderblom, Cormac Owens, Sophie Kaiser, Melissa Fernández-Pinto, Nicola Fenwick, Abigail Evans, Sandra Strauss, Jeremy Whelan, Keith Wheatley and Bernadette Brennan. International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours – EURO EWING 2012 Protocol.
Trials 21. doi: 10.1186/s13063-019-4026-8. Article number: 96(2020) (GEIS 34.)
Stacchiotti S; Ferrari S; Redondo A; Hindi N; Palmerini E; Vaz Salgado, MA; Frezza AM; Casali PG; Gutierrez A; Lopez-Pousa A; Grignani G; Italiano A; LeCesne A; Dumont S; Blay JY; Penel N; Bernabeu D; de Alava E; Karanian M; Morosi C; Brich S; Dagrada GP; Vallacchi V; Castelli C; Brenca M; Racanelli D; Maestro R; Collini P; Cruz J, Martin-Broto J. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.
The Lancet Oncology. vol. 20, issue 9, pp. 1252 - 1262. September 01, 2019. (GEIS 32.)
Ian Judson, James P Morden*, Lucy Kilburn, Michael Leahy, Charlotte Benson, Vivek Bhadri, Quentin Campbell-Hewson, Ricardo Cubedo, Adam Dangoor, Lisa Fox, Ivo Hennig, Katy Jarman, Warren Joubert, Sarah Kernaghan, Antonio López Pousa, Catriona McNeil, Beatrice Seddon, Claire Snowdon, Martin Tattersall, Christy Toms, Javier Martinez Trufero, Judith M Bliss. Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.
Lancet Oncol 2019; vol. 20, issue 7: 1023–34. July 01, 2019. DOI: https://doi.org/10.1016/S1470-
Martin-Broto J; Stacchiotti S; Lopez-Pousa A; Redondo A; Bernabeu D; de Alava E; Casali PG; Italiano A; Gutierrez A; Moura DS; Peña-Chilet M; Diaz-Martin J; Biscuola M; Taron M; Collini P; Ranchere-Vince D; Garcia Del Muro X; Grignani G; Dumont S; Martinez-Trufero J; Palmerini E; Hindi N; Sebio A; Dopazo J; Dei Tos AP; LeCesne A; Blay JY; Cruz J. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
The Lancet. Oncology. 20(1), pp. 134 - 144. 01/01/2019. (GEIS 32.)
César Serrano, Xavier García-del-Muro, Claudia Valverde, Ana Sebio, José Durán, Aránzazu Manzano, Isabel Pajares, Nadia Hindi, Stefania Landolfi, Laura Jiménez, Jordi Rubió-Casadevall, Anna Estival, Javier Lavernia, María José Safont, Carles Pericay, Roberto Díaz-Beveridge, Virginia Martínez-Marín, David Vicente-Baz, Ana Vivancos, Javier Hernández-Losa, Joaquín Arribas, Joan Carles. Clinicopathological and molecular characterization of metastatic gastrointestinal stromal tumors patients with prolonged benefit to frontline imatinib.
The Oncologist, August 2018. doi: 10.1634/theoncologist.2018-0032.
Javier Martin-Broto, Nadia Hindi, Josefina Cruz, Javier Martinez-Trufero, Claudia Valverde, Luis M De Sande, Angeles Sala, Laura Bellido, Ana De Juan, Isabel Sevilla, Jordi Rubió, Roberto Diaz, Ricardo Cubedo, Oscar Tendero, Diego Salinas, Isidro Gracia, Rafael Ramos, Silvia Baguè, Antonio Gutierrez, José Duran-Moreno and Antonio Lopez-Pousa. Relevance of reference centers in sarcoma care and quality item evaluation: results from the prospective registry of the Spanish group for research in sarcoma (GEIS).
The Oncologist 2018;23:1–9. http://dx.doi.org/10.1634/theoncologist.2018-0121.
Alemany R., Moura D.S., Redondo A., Martinez-Trufero J., Calabuig S., Saus C., Obrador-Hevia A., Ramos R., Villar V.H., Valverde C., Vaz M.A., Medina J., Felipe-Abrio I., Hindi N., Taron M, Martin-Broto J. Nilotinib as co-adjuvant treatment with doxorubicin in patients with sarcomas: A phase I trial of the Spanish Group for Research on Sarcoma.
Clin Cancer Research July 23, 2018. doi.org/10.1158/1078-0432.CCR-18-0851.
Pasquali S, Colombo C, Pizzamiglio S, Verderio P, Callegaro D, Stacchiotti S, Martin Broto J, Lopez-Pousa A, Ferrari S, Poveda A, De Paoli A, Quagliuolo V, Jurado JC, Comandone A, Grignani G, De Sanctis R, Palassini E, Llomboart-Bosch A, Dei Tos AP, Casali PG, Picci P, Gronchi A. High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial.
Eur J Cancer. 2018 Apr; 93:28-36.
Kasper B, Lecointe-Artzner E, Wait S, Boldon S, Wilson R, Gronchi A, Valverde C, Eriksson M, Dumont S, Drove N, Kanli A, Wartenberg M. Working to improve the management of sarcoma patients across Europe: a policy checklist.
BMC Cancer. 2018 Apr 16;18(1):424. doi: 10.1186/s12885-018-4320-y.
David S Moura, Rafael Ramos, Antonio Fernandez-Serra, Teresa Serrano, Julia Cruz, Ramiro Alvarez-Alegret, Rosa Ortiz-Duran, Luis Vicioso, Maria Luisa Gomez-Dorronsoro, Xavier Garcia Del Muro, Javier Martinez-Trufero, Jordi Rubio-Casadevall, Isabel Sevilla, Nuria Lainez, Antonio Gutierrez, Cesar Serrano, Maria Lopez-Alvarez, Nadia Hindi, Miguel Taron, José Antonio López-Guerrero, Javier Martin-Broto. Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients.
Oncotarget. 2018 Apr 3; 9(25): 17576–17588.
Xavier García Del Muro, Joan Maurel, Javier Martínez Trufero, Javier Lavernia, Antonio López Pousa, Ramón de Las Peñas, Ricardo Cubedo, José Pablo Berros, Antonio Casado Herráez, Ana de Juan, Javier Martín Broto. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
Invest New Drugs 2018 Jun 12;36(3):468-475. Epub 2018 Mar 12.
Juan Martin-Liberal, Antonio López-Pousa , Javier Martínez-Trufero , Javier Martín-Broto, Ricardo Cubedo, Javier Lavernia, Andrés Redondo, José Antonio López-Martín, Nùria Mulet-Margalef, Xavier Sanjuan, Òscar Martínez Tirado, Xavier García del Muro. Phase II study of gemcitabine plus sirolimus in previously treated patients with advanced soft-tissue sarcoma: a Spanish Group for Research on Sarcomas (GEIS) study.
Target Oncol. 2018 Feb;13(1):81-87.
Martin-Broto J, Redondo A, Valverde C, Vaz MA, Mora J, Garcia Del Muro X, Gutierrez A, Tous C, Carnero A, Marcilla D, Carranza A, Sancho P, Martinez-Trufero J, Diaz-Beveridge R, Cruz J, Encinas V, Taron M, Moura DS, Luna P, Hindi N, Lopez-Pousa A. Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).
Annals of Oncology, Volume 28, Issue 12, 1 December 2017, Pages 2994–2999, https://doi.org/10.1093/annonc/mdx536.
Andrés Redondo, Silvia Bagué, Daniel Bernabeu, Eduardo Ortiz-Cruz, Claudia Valverde, Rosa Alvarez, Javier Martinez-Trufero, Jose A. Lopez-Martin, Raquel Correa, Josefina Cruz, Antonio Lopez-Pousa, Aurelio Santos, Xavier García del Muro, Javier Martin-Broto. Malignant bone tumors (other than Ewing’s): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS).
Cancer Chemother Pharmacol (2017) 80: 1113. https://doi.org/10.1007/s00280-017-3436-0.
J Mora, A Castañeda, S Perez-Jaume, A Lopez-Pousa, E Maradiegue, C Valverde, J Martin-Broto, X Garcia del Muro, O Cruz, J Cruz, J Martinez-Trufero, J Maurel, M A Vaz, E de Alava and C de Torres. GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS).
British Journal of Cancer (2017) 117, 767–774 | doi: 10.1038/bjc.2017.252.
Alessandro Gronchi, Stefano Ferrari, Vittorio Quagliuolo, Javier Martin Broto, Antonio Lopez Pousa, Giovanni Grignani, Umberto Basso, Prof Jean-Yves Blay, Oscar Tendero, Robert Diaz Beveridge, Virginia Ferraresi, Iwona Lugowska, Domenico Franco Merlo, Valeria Fontana, Emanuela Marchesi, Davide Maria Donati, Elena Palassini, Emanuela Palmerini, Rita De Sanctis, Carlo Morosi, Silvia Stacchiotti, Silvia Bagué, Prof Jean Michelle Coindre, Prof Angelo Paolo Dei Tos, Piero Picci, Paolo Bruzzi, Paolo Giovanni Casali. . Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
The Lancet Oncology, Volume 18, ISSUE 6, P812-822, June 01, 2017. DOI:https://doi.org/10.1016/S1470-2045(17)30334-0.
J. Martin-Broto, V. Martinez-Martín, C. Serrano, N. Hindi, J. A. López-Guerrero, R. Ramos-Asensio, A. Vallejo-Benítez, D. Marcilla-Plaza, R. González-Cámpora.Gastrointestinal stromal tumors (GISTs): SEAP–SEOM consensus on pathologic and molecular diagnosis.
Clin Transl Oncol. DOI 10.1007/s12094-016-1581-2
Javier Martin-Broto, Antonio López Pousa, Ramón De las Peñas, Xavier Garcia del Muro, Antonio Gutierrez, Javier Martinez-Trufero, Josefina Cruz, Rosa Alvarez, Ricardo Cubedo, Andrés Redondo, Joan Maurel, Juan A Carrasco, Jose A López-Martin, Angeles Sala, Andrés Meana, Rafael Ramos, Jordi Martinez-Serra, Jose A Lopez-Guerrero, Isabel Sevilla, Carmen Balaña, Angeles Vaz, Ana de Juan, Regina Alemany and Andrés Poveda.Randomized Phase II Study Of Trabectedin And Doxorubicin Compared With Doxorubicin Alone As First Line Treatment In Patients With Advanced Soft Tissue Sarcomas: A Spanish Group For Research On Sarcoma (GEIS) Study.
J Clin Oncol. 2016 Jul 1;34(19):2294-302. doi: 10.1200/JCO.2015.65.3329
Joan Maurel, M.D.; Antonio Pousa López; Silvia Calabuig; Silvia Bague; Xavier Garcia del Muro; Xavier Sanjuan; Jordi Rubio Casadevall; Miriam Cuatrecasas; Javier Martínez Trufero; Carlos Horndler; Joaquin Fra; Claudia Valverde; Andrés Redondo; Andrés Poveda; Isabel Sevilla; Nuria Lainez; Michele Rubini; Xavier García Albéniz; Javier Martin Broto; Enrique de Álava.Phosphorylated-Insulin Growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study.
Clin Sarcoma Res. 2016 Jun 29;6:10
Garcia del Muro X, de Alava E, Artigas V, Bague S, Braña A, Cubedo R, Cruz J, Mulet-Margalef N, Narvaez JA, Martinez Tirado O, Valverde C, Verges R, Viñals J, Martin-Broto J; Spanish Group for Research on Sarcoma.Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS).
Cancer Chemother Pharmacol. 2016 Jan;77(1):133-46. doi: 10.1007/s00280-015-2809-5
López-Pousa A, Martin Broto J, Martinez Trufero J, Sevilla I, Valverde C, Alvarez R, Carrasco Alvarez JA, Cruz Jurado J, Hindi N, Garcia Del Muro X. SEOM Clinical Guideline of management of soft-tissue sarcoma (2016).
Clin Transl Oncol. 2016 Dec;18(12):1213-1220
Martín-Broto J, Hindi N. Targeted treatments of sarcomas and connective tumors beside gastrointestinal stromal tumor.
Curr Opin Oncol. 2016; 28 (4): 338-44.
A. Gronchi, S. Stacchiotti, P. Verderio, S. Ferrari, J. Martin Broto, A. Lopez-Pousa, A. Llombart-Bosch, A.P. Dei Tos, P. Collini, J. Cruz Jurado, A. De Paoli, D.M. Donati, A. Poveda, V. Quagliuolo, A. Comandone, G. Grignani, C. Morosi, A. Messina, R. De Sanctis, S. Bottelli, E. Palassini, P.G. Casali & Piero Picci.Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.
Annals of Oncology 27: 2283–2288, 2016. doi:10.1093/annonc/mdw430. Published online 3 October 2016.
Claudia María Valverde, Javier Martin Broto, Jose A. Lopez-Martin, Cleofe Romagosa, Maria Pilar Sancho Marquez, Juan Antonio Carrasco, Andres Poveda, Sebastian Bauer, Javier Martinez-Trufero, Josefina Cruz, Peter Reichardt, Pablo Luna Fra, Viktor Gruenwald, Oscar Persiva, Diego Varona Porres, Bernd Kasper. . Phase II clinical trial evaluating the activity and tolerability of pazopanib in patients (pts) with advanced and/or metastatic liposarcoma (LPS): A joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) Study.
DOI: 10.1200/JCO.2016.34.15_suppl.11039 Journal of Clinical Oncology 34, no. 15_suppl (May 20, 2016) 11039-11039.
Ander Abarrategi, Juan Tornin, Lucia Martinez-Cruzado, Ashley Hamilton, Enrique Martinez-Campos, Juan P. Rodrigo, M. Victoria González, Nicola Baldini, Javier Garcia-Castro, and Rene Rodriguez. Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies.
Stem Cells International. Volume 2016, Article ID 3631764, 13 pages. http://dx.doi.org/10.1155/2016/3631764.
Paolo G. Casali, Axel Le Cesne, Andres Poveda Velasco, Dusan Kotasek, Piotr Rutkowski, Peter Hohenberger, Elena Fumagalli, Ian R. Judson, Antoine Italiano, Hans Gelderblom, Antoine Adenis, Jörg T. Hartmann, Florence Duffaud, David Goldstein, Javier M. Broto, Alessandro Gronchi, Angelo P. Dei Tos, Sandrine Marréaud, Winette T.A. van der Graaf, John R. Zalcberg, Saskia Litière, and Jean-Yves Blay. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.
J Clin Oncol 2015. 33:4276-4283. DOI: 10.1200/JCO.2015.62.4304.
Rubió-Casadevall J, Borràs J, Carmona-García M, Ameijide A, Gonzalez-Vidal A, Ortiz M, Bosch R, Riu F, Parada D, Martí E, Miró j, Sirvent J, Galceran J, Marcos-Gragera R Correlation between mutational status and survival and second cancer risk assessment in patients with gastrointestinal stromal tumors: a population-based study.
World J Surg Oncol. 2015 Dec;13(1):474. doi:10.1186/s12957-015-0474-0. Epub 2015 Feb 13.
Elena Palassini, Stefano Ferrari, Paolo Verderio, Antonino De Paoli, Javier Martin Broto, Vittorio Quagliuolo, Alessandro Comandone, Claudia Sangalli, Emanuela Palmerini, Antonio Lopez-Pousa, Rita De Sanctis, Stefano Bottelli, Michela Libertini, Piero Picci, Paolo G. Casali, and Alessandro Gronchi. Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide.
DOI: 10.1200/JCO.2015.62.9394. J Clin Oncol 2015. 33:3628-3634. (NCT01710176)
Jordi Rubió-Casadevall MD, Javier Martinez-Trufero MD, Xabier Garcia-Albeniz MD, Silvia Calabuig MD, Antonio Lopez-Pousa MD, Javier Garcia del Muro MD, Joaquin Fra MD, Andrés Redondo MD, Nuria Lainez MD, Andrés Poveda MD, Claudia Valverde MD, Ana De Juan MD, Isabel Sevilla MD, Antonio Casado MD, Raquel Andres MD, Josefina Cruz MD, Javier Martin-Broto MD, Joan Maurel MD, the Spanish Group for Research on Sarcoma (GEIS) GEIS-16 en Annals of Surgical Oncology Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS).
Annals of Surgical Oncology 2015 Jan 22
A Poveda, X García del Muro, JA López Guerrero, V Martínez, I Romero, C Valverde, R Cubedo and J Martín Broto. GEIS 2013 guidelines for gastrointestinal sarcomas (GIST)
Cancer Chemother Pharmacol; 2014 Sep DOI 10.1007/s00280-014-2547-0 PMID: 25193432. Published online. IF: 2.751
Martín-Liberal J, López-Pousa A, Broto JM, Cubedo R, Gallego O, Brendel E, Tirado OM, Del Muro XG. Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.
Invest New Drugs. 2014 Apr;32(2):287-94. PMID:23801301, IF: 3.4
Martín Broto J, Gutiérrez A, Ramos R, López Guerrero JA, Ferrari S, Stachiotti S, Picci P, Calabuig S, Collini P, Gambarotti M, Bagué S, Dei Tos AP, Palassini E, Luna P, Cruz J, Cubedo R, Martínez Trufero J, Poveda A, Casali P, Fernández Serra A, López Pousa A, Gronchi A MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS study.
Mol Cancer Ther. 2014 Jan;13(1):249-59. doi: 10.1158/1535-7163.MCT-13-0406. Epub 2013 Oct 21.
Martín Liberal J, López Pousa A, Martín Broto J, Cubedo R, Gallego O, Brendel E, Martínez Tirado O, García del Muro X Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.
Invest New Drugs. 2014 Apr;32(2):287-94. doi: 10.1007/s10637-013-9989-9. Epub 2013 Jun 26.
Stefhanie Romero, Justyna Szafranska, Eliovel Cabrera, Allan Gonzalez, Ana Peiró, Jaume Llauger, Luis Ortega, Silvia Bague, Belén Canet, Inigo Espinosa & Jaime Prat. Role of tumor-associated macrophages and angiogenesis in desmoid-type fibromatosis.
Virchows Arch. 2012 Aug;461(2):117-22. doi: 10.1007/s00428-012-1265-4. Epub 2012 Jun 29. (Beca Buesa.)
Ruth Sardinha, Teresa Hernández, Susana Fraile, Francesc Tresserra, August Vidal, Maria Carmén Gómez, Aurora Astudillo, Nieves Hernández, Javier Saenz de Santamaría, Jaume Ordi, Luis Gonçalves, Rafael Ramos, Carmen Balañá and Enrique de Álava. Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors.
Clinical Sarcoma Research, 2013, 3:3. doi:10.1186/2045-3329-3-3.
Poveda A, Rivera F, Martín J.SEOM guidelines for gastrointestinal stromal sarcoma (GIST).
Clinical & Translational Oncology. Jul 2012; 14(7):536-540.PMID:22721799. IF: 1.2
Victor Hugo Villar, Oliver Vögler, Jordi Martínez-Serra, Rafael Ramos, Silvia Calabuig-Fariñas, Antonio Gutiérrez, Francisca Barceló, Javier Martín-Broto, Regina Alemany.Nilotinib Counteracts P-Glycoprotein-Mediated Multidrug Resistance and Synergizes the Antitumoral Effect of Doxorubicin in Soft Tissue Sarcomas.
May 2012. Vol. 7, issue 5. e37735. doi.org/10.1371/journal.pone.0037735.
García Del Muro X, Martín J, Maurel J, Cubedo R, Bagué S, de Álava E, Pousa AL, Narváez JA, Ortiz E, Pomés J, Poveda A, Romasanta LP, Tendero O, Viñals JM; Grupo Español de Investigación en Sarcomas (GEIS). Soft tissue sarcomas: clinical practice guidelines.
Med Clin (Barc). 2011 Apr 9;136(9):408.e1-8. PMID:21411112. IF: 1.3
Fuster D, Ayuso JR, Poveda A, Cubedo R, Casado A, Martínez-Trufero J, López-Pousa A, Del Muro XG, Lomeña F, Maurel J, Pons F. Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study.
Q J Nucl Med Mol Imaging. 2011 Dec;55(6):680-7. PMID:21150863. IF: 1.9
Xavier García-del-Muro, Antonio López-Pousa, Joan Maurel, Javier Martín, Javier Martínez-Trufero, Antonio Casado, Auxiliadora Gómez-España, Joaquín Fra, Josefina Cruz, Andrés Poveda, Andrés Meana, Carlos Pericay, Ricardo Cubedo, Jordi Rubió, Ana De Juan, Nuria Laínez, Juan Antonio Carrasco, Raquel de Andrés, and José M. Buesa. Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study.
J Clin Oncol. 2011 Jun 20;29(18):2528-33. doi: 10.1200/JCO.2010.33.6107.
Javier Martín-Broto , Luis Rubio, Regina Alemany & José Antonio López Guerrero. Clinical implications of KIT and PDGFRA genotyping in GIST.
Clinical and Translational Oncology, 2010 Oct;12(10):670-6. doi: 10.1007/s12094-010-0576-7. (Beca Buesa.)
Joan Maurel, Ana Sofia Martins, Andrés Poveda, José Antonio López-Guerrero, Ricardo Cubedo, Antonio Casado, Javier Martínez-Trufero, Juan Ramón Ayuso, Antonio Lopez-Pousa, Xabier Garcia-Albeniz, Xavier Garcia del Muro, and Enrique de Alava.. Imatinib Plus Low-Dose Doxorubicin in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to High-Dose Imatinib. A Phase I-II Study by the Spanish Group for Research on Sarcomas.
Cancer. 2010 Aug 1;116(15):3692-701. doi: 10.1002/cncr.25111.
J Martin; A Gutierrez; J Garcia del Muro; J Maurel; JL González de Sande; J Martinez; A de Juan; N Lainez , F Losa and A Poveda. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST. A Spanish Group for Sarcoma Research (GEIS) Study.
Annals of Oncology 21: 1552–1557, 2010. PMID:20231303, IF: 7.3.
Maurel J, López-Pousa A, de Las Peñas R, Fra J, Martín J, Cruz J, Casado A, Poveda A, Martínez-Trufero J, Balañá C, Gómez MA, Cubedo R, Gallego O, Rubio-Viqueira B, Rubió J, Andrés R, Sevilla I, de la Cruz JJ, Del Muro XG, Buesa JM. Efficacy of Sequential High-Dose Doxorubicin and Ifosfamide Compared With Standard-Dose Doxorubicin in Patients With Advanced Soft Tissue Sarcoma: An Open-Label Randomized Phase II Study of the Spanish Group for Research on Sarcomas.
Journal of Clinical Oncology. Marzo 2009. PMID: 19273704. IF: 18.3
Poveda A, Artigas V, Casado A, Cervera J, García del Muro X, López-Guerrero JA, López-Pousa A, Maurel J, Ortega L, Ramos R, Romero I, José Safont M and Martín J. Guías de la práctica Clínica en los tumores estromales grastrointestinales (GIST): actualización 2008.
Cirugía Española. 2008; 84(1):1-21. PMID:19087862. IF: 0.8
Guías de la práctica Clínica en GIST Clinical & Translational Oncology”, vol. 7, Ext. 2, 2005
Cirugía Española, vol. 84, Ext. 1 / Clinical & Translational Oncology 2008-1. IF:1.2
López-Pousa A, Losa R, Martín J, Maurel J, Fra J, Sierra M, Casado A, García del Muro X, Poveda A, Balaña C, Martínez-Trufero J, Esteban E, Buesa JM. Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study.
British Journal of Cancer (2006), 1 –6. Jun 19;94(12):1797-802. PMID:16721358. IF: 5.0
Losa R, Fra J, López-Pousa A, Sierra M, Goitia A, Uña E, Nadal R, García del Muro X, Gión M, Maurel J, Escudero P, Esteban E, Buesa JM. Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas.
Cancer Chemother Pharmacol. DOI 10.1007/s00280-006-0263-0 May 2006. PMID:16736150 [PubMed - indexed for MEDLINE]. IF: 2.7
Poveda A, López-Pousa A, Martín J, Montalar J, de las Peñas, R, García del Muro X, Cruz J, Maurel J, Escudero P, Casado A, Buesa JM, Martínez-Trufero J, Bover I, Sevilla I, Balañá C, Paredes A, Carles J, Vicent J, Cassinello J. Phase II clinical trial with pegylated liposomal doxorubicin (Caelyx®) / Doxil®) and quality of life evaluation (EORTC QLQC30) in adult patients with advanced soft tissue sarcomas. A Study of the Spanish Group for Research on Sarcomas (GEIS).
Sarcoma. Volume 2006; Article ID 26986, Pages 1-8. PMID:17251655. IF:1.22
López-Pousa A, Martín J, García del MuroX, Bernabé R, Casado A, Balañá C, Sanmartín O, Menéndez MD, Escudero P, Cruz J, Belyakova E, Menéndez D, Buesa JM. Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult. A study of the Spanish Group for Research in Sarcomas (GEIS).
Sarcoma volumen 9 (2005): 127-132. PMID:18521419. IF:1.22
Martín J, Poveda A, Llombart-Bosch A, Ramos R, López-Guerrero JA, García del Muro X, Maurel J, Calabuig S, Gutierrez A, González de Sande JL, Martínez-Trufero J, de Juan A, Laínez N, Losa F, Alija V, Escudero P, Casado A, García P, Blanco R, Buesa JM. Deletions Afecting Codons 557-558 of the c-KIT Gene Indicate a Poor Prognosis in Patients With Completely Resected Gastrointestinal Stromal Tumors: A Study by the Spanish Group for Sarcoma Research (GEIS).
J Clin Oncol. 2005 Sep 1;23(25):6190-8.PMID: 16135486. IF: 18.37
García del Muro X, López-Pousa A, Martín J, Buesa JM, Martínez-Trufero J, Casado A, Poveda A, Cruz J, Bover I, Maurel J. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
Cancer. 2005 Aug 30;104(8):1706-12. PMID: 16134177. IF: 5.2
Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, Emile JF, Gronchi A, Hogendoorn PC, Joensuu H, Le Cesne A, McClure J, Maurel J, Nupponen N, Ray-Coquard I, Reichardt P, Sciot R, Stroobants S, van Glabbeke M, van Oosterom A, Demetri GD. Consensus meeting for the management of gastroinstestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.
Ann Oncol. 2005 Apr;16(4):566-78. PMID: 15781488. IF: 7.3
Maurel J, Buesa JM, López-Pousa A, García del Muro X, Quintana MJ, Martín J, Casado A, Martínez-Trufero J, de las Peñas R, Balañá C. Salvage surgical resection after high-dose ifosfamide (hdif) based regimens in advanced soft tissue sarcoma (asts): a potential positive selection bias – a studi of Spanish group for research on sarcomas (GEIS).
J Surg Oncol. 2004 Oct 1;88(1):44-9. PMID: 15384088. IF:2.5
Maurel J, Fra J, López-Pousa A, García del Muro X, Balañá C, Casado A, Martín J, Martínez-Trufero J, de las Peñas R, Buesa JM; Spanish Group for Research on Sarcomas (GEIS). Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Cancer. 2004 Apr 1;100(7):1498-506. PMID: 15042685. IF: 5.2
Buesa JM, Losa R, Fernández A, Sierra M, Esteban E, Díaz A, López-Pousa A, Fra J. Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation.
Cancer. 2004 Nov 15;101(10):2261-9. PMID: 15484216 IF: 5.2
Buesa JM, Teijido PG, Losa R, Fra J. Treatment of Ifosfamide Encephalopathy with Intravenous Thiamin.
Clinical Cancer Resarch. 2003 Oct 9:4636-7. IF: 7.83
Buesa JM, López-Pousa A, Martín J, Antón A, García del Muro X, Bellmunt J, Arranz F, Valenti V, Escudero P, Menéndez D, Casado A, Poveda A.Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS).
Ann Oncol. 1998 Aug;9(8):871-6. PMID: 9789610. IF: 7.3
Buesa JM, Fra J, Antón A, López-Pousa A, Martín J, García del Muro X, Escudero P, Casado A, Poveda A. Activity of doxorubicin after high-dose ifosfamide in adult patients with advanced soft tissue sarcoma: a study of the Spanish Group for Research on Sarcomas (GEIS).
Ann Oncol. 1998 Jul;9(7):783-5. PMID: 9739447. IF: 7.3